| NKp80 defines a critical step during human natural killer cell development AG Freud, KA Keller, SD Scoville, BL Mundy-Bosse, S Cheng, Y Youssef, ... Cell reports 16 (2), 379-391, 2016 | 115 | 2016 |
| CD56 expression marks human group 2 innate lymphoid cell divergence from a shared NK cell and group 3 innate lymphoid cell developmental pathway L Chen, Y Youssef, C Robinson, GF Ernst, MY Carson, KA Young, ... Immunity 49 (3), 464-476. e4, 2018 | 105 | 2018 |
| A CS1-NKG2D bispecific antibody collectively activates cytolytic immune cells against multiple myeloma WK Chan, S Kang, Y Youssef, EN Glankler, ER Barrett, AM Carter, ... Cancer immunology research 6 (7), 776-787, 2018 | 92 | 2018 |
| IL-18 drives ILC3 proliferation and promotes IL-22 production via NF-κB AR Victor, AP Nalin, W Dong, S McClory, M Wei, C Mao, RD Kladney, ... The Journal of Immunology 199 (7), 2333-2342, 2017 | 81 | 2017 |
| Modulation of immune checkpoint molecule expression in mantle cell lymphoma BK Harrington, E Wheeler, K Hornbuckle, AY Shana’ah, Y Youssef, ... Leukemia & lymphoma, 2019 | 32 | 2019 |
| Adipocytes: a novel target for IL-15/IL-15Rα cancer gene therapy R Xiao, AG Mansour, W Huang, LA Chrislip, RK Wilkins, NJ Queen, ... Molecular Therapy 27 (5), 922-932, 2019 | 27 | 2019 |
| Targeting DNA damage repair functions of two histone deacetylases, HDAC8 and SIRT6, sensitizes acute myeloid leukemia to NAMPT inhibition P Zhang, LT Brinton, K Williams, S Sher, S Orwick, L Tzung-Huei, ... Clinical Cancer Research 27 (8), 2352-2366, 2021 | 20 | 2021 |
| Notch regulates innate lymphoid cell plasticity during human NK cell development AP Nalin, JJ Kowalski, AC Sprague, BK Schumacher, AG Gerhardt, ... The Journal of Immunology 205 (10), 2679-2693, 2020 | 18 | 2020 |
| Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphoma B Mundy-Bosse, N Denlinger, E McLaughlin, N Chakravarti, S Hwang, ... Blood Advances 2 (15), 1818-1827, 2018 | 15 | 2018 |
| TBL1X: At the crossroads of transcriptional and posttranscriptional regulation BA Pray, Y Youssef, L Alinari Experimental hematology 116, 18-25, 2022 | 11 | 2022 |
| Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma SL Sloan, KA Renaldo, M Long, JH Chung, LE Courtney, K Shilo, ... PloS one 16 (5), e0250839, 2021 | 10 | 2021 |
| SOX11 inhibitors are cytotoxic in mantle cell lymphoma SS Jatiani, S Christie, VV Leshchenko, R Jain, A Kapoor, P Bisignano, ... Clinical Cancer Research 27 (16), 4652-4663, 2021 | 9 | 2021 |
| Identification and targeting of the developmental blockade in extranodal natural killer/T-cell lymphoma BL Mundy-Bosse, C Weigel, YZ Wu, S Abdelbaky, Y Youssef, SB Casas, ... Blood cancer discovery 3 (2), 154-169, 2022 | 8 | 2022 |
| Transducin b-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma Y Youssef, V Karkhanis, WK Chan, F Jeney, A Canella, X Zhang, S Sloan, ... haematologica 106 (11), 2927, 2021 | 8 | 2021 |
| PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma SL Sloan, F Brown, M Long, C Weigel, S Koirala, JH Chung, B Pray, ... Blood 142 (10), 887-902, 2023 | 7 | 2023 |
| Hematopathology of the Skin: Clinical & Pathological Approach AA Gru, A Schaffer, A Robson Lippincott Williams & Wilkins, 2023 | 7 | 2023 |
| A sumoylation program is essential for maintaining the mitotic fidelity in proliferating mantle cell lymphoma cells W Hanel, P Lata, Y Youssef, H Tran, L Tsyba, L Sehgal, BW Blaser, ... Experimental Hematology & Oncology 11 (1), 40, 2022 | 7 | 2022 |
| Targeting prmt5 to circumvent acquired ibrutinib resistance in mantle cell lymphoma S Sloan, F Brown, JH Chung, A Prouty, E Wheeler, BK Harrington, ... Blood 134, 4065, 2019 | 5 | 2019 |
| Extranodal natural killer/T-cell lymphomas: current approaches and future directions JC Reneau, P Shindiapina, Z Braunstein, Y Youssef, M Ruiz, S Farid, ... Journal of Clinical Medicine 11 (10), 2699, 2022 | 4 | 2022 |
| PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma F Brown-Burke, I Hwang, S Sloan, C Hinterschied, JB Helmig-Mason, ... Blood Advances 7 (20), 6211-6224, 2023 | 3 | 2023 |
